CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
Hyun Gee Ryoo, Minseok Suh, Keon Wook Kang, Dae-Won Lee, Sae-Won Han, Gi Jeong Cheon
Cancer Research and Treatment. 2023;55(1):334-343.   Published online 2022 April 22    DOI: https://doi.org/10.4143/crt.2021.1022

Excel Download

Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
Cancer Research and Treatment. 2023;55(1):334-343   Crossref logo
Link1 Link2 Link3

Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with177Lu-DOTATATE
Cancer Biotherapy and Radiopharmaceuticals. 2012;27(9):593-599   Crossref logo
Link1 Link2

<sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors
Neuroendocrinology. 2019;110(7-8):662-670   Crossref logo
Link1 Link2

Combined use of 177 Lu‐DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well‐differentiated neuroendocrine tumors: A preclinical study
Journal of Neuroendocrinology. 2022;34(4):   Crossref logo
Link1 Link2 Link3

Safety and response after peptide receptor radionuclide therapy with 177 Lu‐DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial
Journal of Hepato-Biliary-Pancreatic Sciences. 2021;29(4):487-499   Crossref logo
Link1 Link2 Link3

Treatment of neuroendocrine tumours with 177 Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management
Journal of Neuroendocrinology. 2022;34(4):   Crossref logo
Link1 Link2 Link3

177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models
Dose-Response. 2021;19(1):155932582199014   Crossref logo
Link1 Link2 Link3

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with177Lu-DOTATATE and90Y-DOTATOC
Cancer Biotherapy and Radiopharmaceuticals. 2009;24(6):659-665   Crossref logo
Link1 Link2

Single centre retrospective review of outcome of 177 Lu‐DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors
Journal of Neuroendocrinology. 2022;34(11):   Crossref logo
Link1 Link2 Link3

Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with68Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy
Molecular Imaging. 2010;9(6):7290.2010.00035   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.